| Income Statement | 2025-06-30 | |||
|---|---|---|---|---|
| Research and development | 6,232 | |||
| General and administrative | 4,643 | |||
| Loss (gain) on fair value remeasurement of contingent consideration | -153 | |||
| Total costs and expenses | 11,028 | |||
| Loss from operations | -11,028 | |||
| Interest income | 407 | |||
| Interest expense | 1,081 | |||
| Grant income | 547 | |||
| Total other income (expense) | -127 | |||
| Net loss | -11,155 | |||
| Earnings per share, basic | -1.71 | |||
| Earnings per share, diluted | -1.71 | |||
| Weighted average number of shares outstanding, basic | 6,513,108 | |||
| Weighted average number of shares outstanding, diluted | 6,513,108 | |||
KALA BIO, Inc. (KALA)
KALA BIO, Inc. (KALA)